A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome
about
Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trialsClinical development of demethylating agents in hematologyDecitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysisEfficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemiaPlatelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients.Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b StudyA prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndromeBetter transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts.Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy aloneThe role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study.Increased PD-1/STAT1 ratio may account for the survival benefit in decitabine therapy for lower risk myelodysplastic syndrome.A comparison of therapeutic dosages of decitabine in treating myelodysplastic syndrome: a meta-analysis.Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: A systematic review and meta-analysis
P2860
Q26745731-D61169F1-C683-4D69-B7A0-862584B4BB87Q34395179-3C221A09-8F96-48D0-86BB-F1DD88335930Q35153059-7D31DEFE-DD3F-43E2-B778-EC475ADCC782Q35742564-B7991DA7-B798-4E7A-AE31-DFF980F4E3ADQ36140902-9BC37FC8-E2B1-431B-98E4-F904A750B316Q36327153-38863C3B-86D0-4B7A-8141-D55EE815DAD1Q36689145-761AB7E9-07B1-4275-91E4-7269C3436C9CQ37707098-375442A0-9C0B-47C1-874C-6771FCC08D9EQ37742267-F694A9BB-A3D4-4890-B4EF-63893D93C61BQ38160051-52429CF2-3C13-478A-889A-63CC61D96C04Q38540859-3EF525D9-54AE-4BB8-9D78-B453417EFE13Q41331089-C8073D27-2479-41F0-A7C0-1D2473F30718Q49021366-CA596153-C465-4403-B872-820B9D66F6A2Q54363269-F5C5D037-00B4-4EAA-826F-2275C87269D4Q58706592-796472FF-2A16-4645-B12D-76729EB1EED4
P2860
A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A prospective multicenter obse ...... with myelodysplastic syndrome
@ast
A prospective multicenter obse ...... with myelodysplastic syndrome
@en
type
label
A prospective multicenter obse ...... with myelodysplastic syndrome
@ast
A prospective multicenter obse ...... with myelodysplastic syndrome
@en
prefLabel
A prospective multicenter obse ...... with myelodysplastic syndrome
@ast
A prospective multicenter obse ...... with myelodysplastic syndrome
@en
P2093
P2860
P1433
P1476
A prospective multicenter obse ...... with myelodysplastic syndrome
@en
P2093
Chul Won Choi
Eunkyung Park
Hoon-Gu Kim
Je-Hwan Lee
Jinny Park
Jun Ho Jang
Seong Kyu Park
Seonyang Park
Sung-Hyun Kim
Yeo-Kyeoung Kim
P2860
P304
P356
10.3324/HAEMATOL.2011.046078
P577
2011-06-09T00:00:00Z